Centenarian Exomes as a Tool for Evaluating the Clinical Relevance of Germline Tumor Suppressor Mutations.
Bulgarian
centenarians
reevaluation of clinical significance
tumor suppressor genes
whole-exome sequencing
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
21
11
2020
Statut:
ppublish
Résumé
The aim of the present study was to evaluate the clinical relevance of mutations in tumor suppressor genes using whole-exome sequencing data from centenarians and young healthy individuals. Two pools, one of centenarians and one of young individuals, were constructed and whole-exome sequencing was performed. We examined the whole-exome sequencing data of Bulgarian individuals for carriership of tumor suppressor gene variants. Of all variants annotated in both pools, 5080 (0.06%) are variants in tumor suppressor genes but only 46 show significant difference in allele frequencies between the two studied groups. Four variants (0.004%) are pathogenic/risk factors according to single nucleotide polymorphism database: rs1566734 in Based on their high minor allele frequencies and presence in the centenarian group, we could reclassify them from pathogenic/risk factors to benign. Our study shows that centenarian exomes can be used for re-evaluating the clinically uncertain variants.
Identifiants
pubmed: 32233832
doi: 10.1177/1533033820911082
pmc: PMC7132786
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533033820911082Références
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2782-5
pubmed: 18843023
Prostate. 2008 Mar 1;68(4):354-9
pubmed: 18189233
Exp Aging Res. 2012;38(5):584-92
pubmed: 23092224
Endocr Relat Cancer. 2010 Oct 29;17(4):1001-6
pubmed: 20823296
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Genet Mol Res. 2013 Dec 04;12(4):6268-74
pubmed: 24338422
Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):359-67
pubmed: 26543082
DNA Cell Biol. 2010 Nov;29(11):669-74
pubmed: 20590474
Prostate. 2008 Dec 1;68(16):1790-7
pubmed: 18767027
J Oral Pathol Med. 2008 May;37(5):271-7
pubmed: 18410587
PeerJ. 2017 Feb 15;5:e3003
pubmed: 28229027
Nucleic Acids Res. 2016 Jan 4;44(D1):D1023-31
pubmed: 26590405
Prostate. 2010 Nov 1;70(15):1716-27
pubmed: 20564318
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Nat Rev Genet. 2014 Nov;15(11):749-63
pubmed: 25246196
J Cancer Res Clin Oncol. 2010 Feb;136(2):249-59
pubmed: 19672627
Nat Protoc. 2015 Oct;10(10):1556-66
pubmed: 26379229
Oncol Lett. 2015 May;9(5):2425-2429
pubmed: 26137085
Carcinogenesis. 2007 Feb;28(2):423-6
pubmed: 16956908
Exp Mol Med. 2015 Aug 07;47:e176
pubmed: 26251261
Mol Med Rep. 2011 Sep-Oct;4(5):901-12
pubmed: 21725594
Nucleic Acids Res. 2017 Jan 4;45(D1):D833-D839
pubmed: 27924018
J Appl Genet. 2019 Feb;60(1):57-62
pubmed: 30661225
BMC Cancer. 2007 Aug 16;7:162
pubmed: 17705814